Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

Min Yao, Nicholas Galanopoulos, Pierre Lavertu, Pingfu Fu, Michael Gibson, Athanassios Argiris, Rod Rezaee, Chad Zender, Jay Wasman, Mitchell Machtay, Panos Savvides

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m2) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy.

Original languageEnglish (US)
Pages (from-to)1665-1671
Number of pages7
JournalHead and Neck
Volume37
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

docetaxel
Radiation
Radiotherapy
Survival
Disease-Free Survival
Mucositis
Dermatitis
Treatment Failure
Hemorrhage
Neoplasm Metastasis
Recurrence
Bevacizumab
Carcinoma, squamous cell of head and neck

Keywords

  • bevacizumab
  • chemoradiation
  • docetaxel
  • head and neck cancer
  • radiation

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. / Yao, Min; Galanopoulos, Nicholas; Lavertu, Pierre; Fu, Pingfu; Gibson, Michael; Argiris, Athanassios; Rezaee, Rod; Zender, Chad; Wasman, Jay; Machtay, Mitchell; Savvides, Panos.

In: Head and Neck, Vol. 37, No. 11, 01.11.2015, p. 1665-1671.

Research output: Contribution to journalArticle

Yao, M, Galanopoulos, N, Lavertu, P, Fu, P, Gibson, M, Argiris, A, Rezaee, R, Zender, C, Wasman, J, Machtay, M & Savvides, P 2015, 'Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck', Head and Neck, vol. 37, no. 11, pp. 1665-1671. https://doi.org/10.1002/hed.23813
Yao, Min ; Galanopoulos, Nicholas ; Lavertu, Pierre ; Fu, Pingfu ; Gibson, Michael ; Argiris, Athanassios ; Rezaee, Rod ; Zender, Chad ; Wasman, Jay ; Machtay, Mitchell ; Savvides, Panos. / Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. In: Head and Neck. 2015 ; Vol. 37, No. 11. pp. 1665-1671.
@article{16ac2dd5b0a74ce38b1a2fe0b0a0cfa3,
title = "Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck",
abstract = "Background The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m2) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7{\%}, 68.2{\%}, 84.5{\%}, and 80.5{\%}, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy.",
keywords = "bevacizumab, chemoradiation, docetaxel, head and neck cancer, radiation",
author = "Min Yao and Nicholas Galanopoulos and Pierre Lavertu and Pingfu Fu and Michael Gibson and Athanassios Argiris and Rod Rezaee and Chad Zender and Jay Wasman and Mitchell Machtay and Panos Savvides",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/hed.23813",
language = "English (US)",
volume = "37",
pages = "1665--1671",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

AU - Yao, Min

AU - Galanopoulos, Nicholas

AU - Lavertu, Pierre

AU - Fu, Pingfu

AU - Gibson, Michael

AU - Argiris, Athanassios

AU - Rezaee, Rod

AU - Zender, Chad

AU - Wasman, Jay

AU - Machtay, Mitchell

AU - Savvides, Panos

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m2) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy.

AB - Background The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m2) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy.

KW - bevacizumab

KW - chemoradiation

KW - docetaxel

KW - head and neck cancer

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=84944072748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944072748&partnerID=8YFLogxK

U2 - 10.1002/hed.23813

DO - 10.1002/hed.23813

M3 - Article

C2 - 24954745

AN - SCOPUS:84944072748

VL - 37

SP - 1665

EP - 1671

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 11

ER -